'Recently the U.S. Food and Drug Administration approved a new drug for metastatic colon cancer.
Lonsurf is a combination of two drugs, trifluridine and tipiracil. Its most common side effects are life-threatening anemia, a decrease in infection-fighting white blood cells and blood platelets, physical weakness, and extreme fatigue. It also causes nausea, decreased appetite, diarrhea, vomiting, abdominal pain and fever.
The drug maker announced the approval as a milestone offering significant survival benefits to patients. But does it?'